Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...
aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...
LBBB is linked to electrical abnormalities, causing inefficient heart pumping, dilation, and systolic dysfunction. The study found LBBB associated with increased heart failure risk, surpassing other ...
Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.
Department of Ultrasonography, Henan Provincial People’s Hospital, Zhengzhou Henan, China Objective: This study aims to explore the value of layer-specific strain in evaluating the differences in left ...
Every once in a while, a breakthrough doesn't just advance medicine—it changes the conversation entirely. SUNNYVALE, Calif., April 17, 2025 /PRNewswire/ -- EBR Systems, Inc. (ASX: EBR) has received ...
Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback